FAN Hao-zhi, YUE Ming, SHAO Jian-guo, XUE Hong, TIAN Ting, WU Jing-jing, YAO Min, HUANG Peng, YU Rong-bin, ZHANG Yun. Association of C-C chemokine receptor type 5 Gene Polymorphisms with the Effectiveness of Interferon Therapy among Patients with Chronic Hepatitis C[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2018, 22(10): 1020-1023,1027. doi: 10.16462/j.cnki.zhjbkz.2018.10.010
Citation:
FAN Hao-zhi, YUE Ming, SHAO Jian-guo, XUE Hong, TIAN Ting, WU Jing-jing, YAO Min, HUANG Peng, YU Rong-bin, ZHANG Yun. Association of C-C chemokine receptor type 5 Gene Polymorphisms with the Effectiveness of Interferon Therapy among Patients with Chronic Hepatitis C[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2018, 22(10): 1020-1023,1027. doi: 10.16462/j.cnki.zhjbkz.2018.10.010
FAN Hao-zhi, YUE Ming, SHAO Jian-guo, XUE Hong, TIAN Ting, WU Jing-jing, YAO Min, HUANG Peng, YU Rong-bin, ZHANG Yun. Association of C-C chemokine receptor type 5 Gene Polymorphisms with the Effectiveness of Interferon Therapy among Patients with Chronic Hepatitis C[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2018, 22(10): 1020-1023,1027. doi: 10.16462/j.cnki.zhjbkz.2018.10.010
Citation:
FAN Hao-zhi, YUE Ming, SHAO Jian-guo, XUE Hong, TIAN Ting, WU Jing-jing, YAO Min, HUANG Peng, YU Rong-bin, ZHANG Yun. Association of C-C chemokine receptor type 5 Gene Polymorphisms with the Effectiveness of Interferon Therapy among Patients with Chronic Hepatitis C[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2018, 22(10): 1020-1023,1027. doi: 10.16462/j.cnki.zhjbkz.2018.10.010
Objective To explore the association between C-C chemokine receptor type 5 (CCR5) gene polymorphisms and the effectiveness of interferon (IFN) therapy in chronic hepatitis C (CHC) patients, so as to provide a basis for guiding CHC treatment and prognosis evaluation. Methods A total of 348 CHC were included in this study. All patients received standard 48-week IFN therapy and were followed up for 24 weeks. Two single nucleotide polymorphisms (SNPs) rs10800874 and rs746492 in CCR5 gene were genotyped by Taqman-MGB methods, and the relationship between the SNPs and the treatment effectiveness was analyzed. Results Logistic regression analysis showed that CHC patients carrying the rs10800874 TG (adjusted OR=1.87, 95% CI=1.08-3.25, P=0.026) and GG (adjusted OR=1.96, 95% CI 1.01-3.82, P=0.048) genotypes were more likely to have a sustained virological response (SVR), compared with CHC patients carrying TT genotype. The results of further stratified analysis demonstrated that the association between carrying the rs10800874-G allele and SVR in females, high glucose levels and low alpha-fetoprotein levels remained significant (all P<0.05). Conclusions The CCR5 rs10800874-G allele is a protective factor for SVR among CHC patients receiving standard IFN therapy.